Testing a seizure medicine for people whose cancer spread to the brain's movement area
Original title: Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so we do not know yet if it helps.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests whether a seizure medicine can stop seizures before they ever start.
Who this trial is for. This trial is for people whose cancer has spread to the primary motor cortex. That is the part of the brain that controls movement. These are people who have not had a seizure. Some are picked at random to take levetiracetam: A medicine that helps stop seizures. Many people with a brain tumor take it. In some people it also brings a short temper, anger or low mood. Tell your team if you notice that. See the glossary, also called Keppra. Others get usual care, which does not include this medicine.
Where it stands. This trial has not reported results. It is comparing people who take the medicine with people who do not. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Right now, usual care does not include this medicine to prevent seizures in this group. This trial is testing whether taking it ahead of time is better. Someone who fits might ask their care team about it.
What it doesn't mean: This does not mean the medicine works. A trial is a test, not proven care. Being in one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, September 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.